SCIEX Launches Next-generation TripleTOF 5600 System

The new TripleTOF® 5600+ System delivers new innovation for biomolecule research with MS/MS with SWATH® Acquisition and supports a higher level of selectivity when coupled with SelexION™ Technology.

May 21, 2012

SCIEX, a global leader in life science analytical technologies, today announced the launch of the second generation of the TripleTOF® 5600 System.  The new TripleTOF® 5600+ System delivers new innovation for biomolecule research with MS/MSALL with SWATH® Acquisition and supports a higher level of selectivity when coupled with SelexION™ Technology. The new system also comes with software that is capable of supporting 21 CFR Part 11 compliance, making TripleTOF® technology more accessible for regulated labs in the pharmaceutical industry. The TripleTOF 5600+ is on display at this week's American Society of Mass Spectrometry (ASMS) conference in Vancouver.

The new TripleTOF® 5600+ system represents an advancement in accurate mass technology that combines high resolution with high sensitivity and high speed. This new system builds on the proven innovation of the TripleTOF® 5600, which was launched at ASMS in 2010. The new TripleTOF® 5600+ system is now the industry's fastest, high sensitivity and high-resolution mass spectrometer for simultaneous high-performance qualitative and quantitative analysis. A built-in capability to support SelexION™ Technology also adds versatility and breakthrough levels of selectivity.

By incorporating support for MS/MSALL with SWATH® Acquisition on the TripleTOF® 5600+ platform, researchers will be able to obtain more information about proteins, peptides and other biomolecules from a sample than ever before. SWATH® Acquisition is a groundbreaking mass spectrometry-based technique that quantifies nearly all peptides and proteins in a sample from a single analysis. The TripleTOF® 5600+ is the only platform in the industry that has the speed, sensitivity and dynamic range to enable SWATH® Acquisition, which was developed through a collaboration with Ruedi Aebersold, Ph.D., a leading proteomics researcher who is based at ETH Zurich. The scientific community has already responded with positive feedback.

"The combination of the SCIEX TripleTOF® 5600+ system and the recent development of SWATH® acquisition has completely changed how I think about designing and implementing quantitative proteomics studies," said Bradford W. Gibson, Ph.D., Professor & Director of Chemistry and Mass Spectrometry, Buck Institute for Research on Aging. "The high resolution and fast scanning capabilities of the TripleTOF have made it possible for the first time to acquire MS and MS/MS ion intensity data on essentially all peptides in a single run that can be mined both immediately and retrospectively. This is truly a revolutionary combination of instrumentation technologies and software innovation."

SCIEX is also extending the utility of TripleTOF® technology for use in pharmaceutical laboratories, addressing a need for compliance to 21 CFR Part 11 for electronic records and signatures. With software that is capable of supporting 21 CFR Part 11 compliance, the new TripleTOF solution opens up new possibilities for drug discovery labs to meet this regulatory requirement.

"The launch of the TripleTOF 5600+ System is exactly two years after the first TripleTOF instrument broke new ground in the mass spectrometry industry and changed the way scientists approach analyses of drugs, contaminants and proteins," said Dave Hicks, Vice President of the Pharma & Academic Business at SCIEX. "Now, we are continuing the evolution of the TripleTOF platform with new functionality that directly addresses feedback from customers who want to push the limits in their quantitative and qualitative analyses."

Compatibility with SelexION™ Technology is another new feature of the TripleTOF® 5600+ system developed in response to customer feedback garnered ever since SCIEX launched it at ASMS in 2011. SelexION™ Technology delivers a new dimension of selectivity by adding differential ion mobility to conventional mass spectrometry for both quantitative and qualitative analysis. It significantly improves selectivity and performance for any application requiring the separation of isobaric species, isolation of challenging co-eluting contaminants and elimination of high background noise. This advancement reduces sample preparation requirements and improves overall data quality.


SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.

With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit

SCIEX social: @SCIEXnewsLinkedIn, and Facebook.

AB Sciex is operating as SCIEX.
© 2018 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.

For research use only. Not for use in diagnostic procedures.

Contact Information
Lulu VanZandt
Program Manager, Brand, Public Relations and Social Media, SCIEX
+1 (508) 383-7163
M: +1 (508) 782-9484